Saffron extract and sleep
Results of a four-week Safr’Inside study in people with moderate sleep complaints.
Key points
- In one four-week study in adults with moderate sleep complaints, the pooled Safr’Inside groups rated sleep symptoms slightly better than the placebo group. In people with such complaints, this extract may slightly ease subjective sleep difficulties over four weeks. [1] See the evidence 1
- In the same study, self-rated sleep quality was higher with 20 and 30 mg of Safr’Inside than with placebo. In people with such complaints, this extract may slightly improve their own rating of sleep quality over four weeks. [1] See the evidence 1 2
Practical guide
Check the conclusions and whether they apply to your situation.
Self-rated sleep symptoms and sleep quality were assessed separately.
Key points
Why these conclusions
The Safr’Inside study
Adults with moderate insomnia symptoms received standardized Safr’Inside at 20 or 30 mg or placebo about one hour before bedtime for four weeks. In the pooled extract groups, sleep symptoms on the AIS scale decreased slightly more than with placebo. [1]
In that study, self-rated sleep quality on the SQS scale was higher with both extract doses. The clinical importance of the size of the changes remains uncertain. [1]
Saffron is the dried stigmas of Crocus sativus. The spice, standardized Safr’Inside extract and individual saffron compounds differ in composition; the RCT result concerns the extract studied. [2] [1]
Gastrointestinal adverse events, usually mild, have been reported in saffron studies; not all studies collected them systematically. [3]
After four weeks, AIS sleep symptoms decreased by 0.95 points more than with placebo when the 20 and 30 mg/day Safr’Inside groups were pooled.
| Parameter | Data |
|---|---|
| Result | After four weeks, AIS sleep symptoms decreased by 0.95 points more than with placebo when the 20 and 30 mg/day Safr’Inside groups were pooled. Adjusted AIS difference for pooled 20 and 30 mg versus placebo −0.95 points (95% CI −1.79…−0.11), p=0.027; mean changes −1.54 and −1.96 versus −0.71. |
| Participants | 165 adults with moderate insomnia symptoms, 150 completed |
| Form | Standardized Safr’Inside extract orally about one hour before bedtime |
| Dose | 20 or 30 mg/day, pooled active groups |
| Dose basis | 20 or 30 mg/day, pooled active groups |
| Comparator | Maltodextrin |
| Duration | 4 weeks |
| Confidence | 2/4: Precision: short follow-up and uncertain clinical importance of the size of the change.; Consistency: no grounds for a separate downgrade.; Applicability to the specified group: the measure directly addresses the stated narrow research question.; Possible publication bias: no specific data for a separate downgrade.; Study methods: subjective outcomes, losses and secondary comparisons. |
| Evidence base | 1 trial |
| Sources | [1] |
After four weeks, self-rated SQS sleep quality was 1.02 points higher with 20 mg/day Safr’Inside than with placebo.
| Parameter | Data |
|---|---|
| Result | After four weeks, self-rated SQS sleep quality was 1.02 points higher with 20 mg/day Safr’Inside than with placebo. At week 4, adjusted SQS contrast +1.02 points (95% CI +0.43…+1.62), p<0.001 for 20 mg versus placebo. |
| Participants | 165 adults with moderate insomnia symptoms, 150 completed |
| Form | Standardized Safr’Inside extract orally about one hour before bedtime |
| Dose | 20 mg/day |
| Dose basis | 20 mg/day |
| Comparator | Maltodextrin |
| Duration | 4 weeks |
| Confidence | 2/4: Precision: short follow-up and uncertain clinical importance of the size of the change.; Consistency: no grounds for a separate downgrade.; Applicability to the specified group: the measure directly addresses the stated narrow research question.; Possible publication bias: no specific data for a separate downgrade.; Study methods: subjective outcomes, losses and secondary comparisons. |
| Evidence base | 1 trial |
| Sources | [1] |
After four weeks, self-rated SQS sleep quality was 0.82 points higher with 30 mg/day Safr’Inside than with placebo.
| Parameter | Data |
|---|---|
| Result | After four weeks, self-rated SQS sleep quality was 0.82 points higher with 30 mg/day Safr’Inside than with placebo. At week 4, adjusted SQS contrast +0.82 points (95% CI +0.22…+1.41), p=0.004 for 30 mg versus placebo. |
| Participants | 165 adults with moderate insomnia symptoms, 150 completed |
| Form | Standardized Safr’Inside extract orally about one hour before bedtime |
| Dose | 30 mg/day |
| Dose basis | 30 mg/day |
| Comparator | Maltodextrin |
| Duration | 4 weeks |
| Confidence | 2/4: Precision: short follow-up and uncertain clinical importance of the size of the change.; Consistency: no grounds for a separate downgrade.; Applicability to the specified group: the measure directly addresses the stated narrow research question.; Possible publication bias: no specific data for a separate downgrade.; Study methods: subjective outcomes, losses and secondary comparisons. |
| Evidence base | 1 trial |
| Sources | [1] |
Saffron is the dried stigmas of Crocus sativus. The spice, standardized Safr’Inside extract and individual saffron compounds differ in composition; the RCT result concerns the extract studied.
Saffron is the dried stigmas of Crocus sativus. The spice, standardized Safr’Inside extract and individual saffron compounds differ in composition; the RCT result concerns the extract studied. [2] [1]
Gastrointestinal adverse events, usually mild, have been reported in saffron studies; not all studies collected them systematically.
Gastrointestinal adverse events, usually mild, have been reported in saffron studies; not all studies collected them systematically. [3]
Sources
- Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC12281372/
- CPG Sec 525.750 Spices - Definitions. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-525750-spices-definitions
- Adverse Events of Saffron (Crocus sativus L.): Systematic Review of Current Evidence. https://pubmed.ncbi.nlm.nih.gov/42057871/
Methodology: Subpages evidence-led supplement pipeline v1